erlotinib has been researched along with lfm a13 in 1 studies
Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (lfm a13) | Trials (lfm a13) | Recent Studies (post-2010) (lfm a13) |
---|---|---|---|---|---|
221 | 0 | 180 | 24 | 0 | 10 |
Protein | Taxonomy | erlotinib (IC50) | lfm a13 (IC50) |
---|---|---|---|
Tyrosine-protein kinase BTK | Mus musculus (house mouse) | 2.5 | |
Tyrosine-protein kinase BTK | Homo sapiens (human) | 2.5 | |
Serine/threonine-protein kinase PLK3 | Homo sapiens (human) | 7.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
1 other study(ies) available for erlotinib and lfm a13
Article | Year |
---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |